TITLE:
Retrospective Analysis of S-1 plus Bevacizumab as Maintenance Therapy after Induction of S-1 and Oxaliplatin (SOX) plus Bevacizumab as First-Line Chemotherapy in Patients with Metastatic Colorectal Cancer
AUTHORS:
Yasutake Uchima, Naoki Aomatsu, Gen Tsujio, Takehiko Iwauchi, Shinji Matsutani, Hiroto Tanaka, Hironari Miyamoto, Takuma Okada, Shigeaki Kurihara, Toshiki Hirakawa, Keiichiro Hirata, Junya Morimoto, Shigehito Yamagata, Kazuhiro Takeuchi
KEYWORDS:
S-1, Oxaliplatin, Bevacizumab, Colorectal Cancer
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.11 No.2,
January
22,
2020
ABSTRACT: Background:
The SOFT study was a phase III trial designed to validate the non-inferiority of S-1 and oxaliplatin (SOX) plus
bevacizumab to mFOLFOX6 plus bevacizumab in terms of PFS in patients
with metastatic colorectal cancer (mCRC) who had not previously received
chemotherapy. In this study, we retrospectively reviewed cases in which S-1
plus bevacizumab as maintenance therapy after induction of S-1 and Oxaliplatin
(SOX) plus bevacizumab as first-line chemotherapy in patients with metastatic
colorectal cancer was applied in order to evaluate its efficacy and safety in
clinical practice. Material and method: Among the 40 patients with mCRC at the
Fuchu Hospital who received SOX plus bevacizumab
as a first line treatment between August 2013 and December 2018. The eligible
patients had histologically confirmed mCRC. On day 1 of each 3-week period during the study,
patients in the SOX plus bevacizumab received a 7.5 mg/kg intravenous infusion
of bevacizumab, followed by an intravenous infusion of 130 mg/m2 oxaliplatin.
S-1 (40 - 60 mg) was
administered orally two times per day from after dinner on day 1 to after breakfast on day 15, followed by a 7-day rest. Results: The median PFS was 15.0 months and median OS was
36.0 months. The response rate (RR: complete pus partial response) was 85.0%,
and the disease control rate (DCR: RR plus stable disease) was 92.5%. The most common adverse
events with SOX plus bevacizumab were hypertension (50%), neurosensory toxicity
(50%), anorexia (32.5%), fatigue (45%),
pigmentation (39%), Neutrophil count decreased (30%), and platelet count decreased (40%). The most
common grade 3/4 adverse events were
neurosensory toxicity (5%) and fatigue (9%). Conclusion: This study revealed that
the survival benefit of S-1 and oxaliplatin (SOX) plus bevacizumab in Japanese
patients with mCRC was like that observed in previous clinical trials.
Therefore, S-1 and oxaliplatin (SOX) plus bevacizumab can be considered as
routine first-line treatment option for patients with mCRC.